Table of Contents
- ABOUT DATAMONITOR HEALTHCARE
- About the Infectious & Respiratory Disease pharmaceutical analysis
team
- CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into the Infectious Disease market
- Related reports
- Upcoming reports
- CHAPTER 2 MARKET DEFINITIONS
- Anatomical Therapeutic Classifications
- Antibacterials
- Antifungals
- Antivirals excluding HIV
- HIV
- Geographic coverage
- License status
- CHAPTER 3 BACKGROUND AND OVERVIEW
- Infectious Disease market performance
- Volume sales are showing a nominal decline in both the medium and
short term
- Volume sales are relatively low by comparison to other ATCs
- Sharp decline in value growth
- Infectious Disease sector comparison
- Sector key metrics
- Market attractiveness
- Leading molecules
- Top 10 company involvement
- Market leader performance and portfolio composition
- Sector reliance
- Geographic orientation
- CHAPTER 4 ANTIBACTERIALS
- Disease background
- Pathogen and pathogen type
- Antibiotic classes
- Penicillins
- Cephalosporins
- Fluoroquinolones
- Macrolides and ketolides
- Other significant classes
- Site of infection
- Hospital versus community markets
- Commercial analysis
- Market size and structure
- Geographic focus
- Brand and company focus
- Top five company analysis
- Pfizer - success through accession, but will the formula work again?
- Johnson & Johnson - cornering the market ahead of time
- Abbott - will the last one out, turn off the lights?
- Novartis - the best of both worlds: mixing high value brands with a
generic assault
- Sanofi-Aventis - what will you be remembered for: Tavanic and
Claforan, or Synercid and Ketek?
- Key portfolio management strategies - Antibiotics: Pfizer
- Softening the blow of Zithromax
- Zyvox and Zeven: creating a unified front
- CHAPTER 5 ANTIFUNGALS
- Disease background
- Unmet need - driving product development of premium products
- Changing patient populations
- Transplant patients
- Cancer
- HIV
- Children and neonates
- The antifungal drug explosion
- The shifting spectrum of causative pathogens
- Linking patients to pathogens
- From Candida to Aspergillus and beyond - changing fungal epidemiology
- Diagnostic capabilities
- Commercial analysis
- Market size and structure
- J2A0 and Azole market devaluation pulls market down
- Echinocandins - a price war beckons
- Polyenes - liposomal formulations sidelined
- Others
- Geographic focus
- Brand and company focus
- Top five company analysis
- Novartis - one hit wonder?
- Pfizer - the best of the rest
- Merck & Co - the Cancidas honeymoon is over
- Johnson & Johnson - let down by licensing opportunities?
- Astellas Pharma - a simple value proposition in a costly market
- CHAPTER 6 ANTIVIRALS
- Disease background
- Hepatitis
- HCV management
- HBV management
- Respiratory viruses
- Influenza
- Respiratory syncytial virus (RSV)
- HSV, CMV and similar viruses
- Herpes simplex virus (HSV)
- Varicella zoster virus (VZV)
- Cytomegalovirus (CMV)
- Commercial analysis
- Market size and structure
- Hepatitis
- Respiratory viruses
- HSV, CMV and similar viruses
- Geographic focus
- Brand and company focus
- Top five company analysis
- GSK - opting for a biological future
- Roche - the need for sector dominance
- Schering-Plough - back-footed, but fighting on
- Novartis - would generics be a better option?
- Gilead - can leveraging portfolios yield sustainable growth?
- CHAPTER 7 HIV
- Disease background
- Patient population
- Drug class overviews
- Nucleoside reverse transcriptase inhibitors
- Non-nucleotide reverse transcriptase inhibitors
- Protease inhibitors
- Entry inhibitors
- Commercial analysis
- Market size and structure
- Geographic focus
- Brand and company focus
- Top five HIV company analysis
- GSK - a behemoth with an ageing proposition
- Gilead - young turk or smooth operator?
- BMS - all about timing
- Abbott - can in-licensing be relied on?
- Roche - going for broke
- Key portfolio management strategies - HIV FDC Case Study
- GSK - plugging the pipeline let-down gap
- Gilead - keeping options open - balancing FDCs with new product
- BMS - what is there to lose?
- FDCs from generics - Waiting in the wings
- BIBLIOGRAPHY
- Literature
- Websites and similar
- Other sources
- Datamonitor sources
- APPENDIX A
- CHAPTER 8 APPENDIX B
- About Datamonitor
- About Datamonitor Healthcare
- About the Infectious & Respiratory Disease analysis team
- Key therapy team members
- Holger Rovini, Head of Respiratory and Infectious Diseases
- Disclaimer
- List of Tables
- Table 1: Key dynamics - Infectious Disease versus other key
therapeutic sectors, 7MM, 2002-06
- Table 2: Infectious disease sector dynamic comparisons - key volume
and value metrics, 7MM, 2002-06
- Table 3: Market attractiveness - product, company and generic
dominance by sector, 7MM, 2006
- Table 4: Top selling molecules across the antibiotic, antifungal,
antiviral and HIV sectors, 7MM, 2006
- Table 5: Top 10 companies by revenue across the antibiotic,
antifungal, antiviral and HIV sectors, 7MM, 2006
- Table 6: Top 10 company portfolio bias - percentage value sales across
the antibiotic, antifungal, antiviral and HIV sectors, 7MM, 2006
- Table 7: Regional revenues - top 10 companies, rest of market and
total market sales across the antibiotic, antifungal, antiviral and HIV
sectors, 7MM, 2006
- Table 8: Examples of clinically significant pathogens by Gram stain
- Table 9: Key pathogens targeted by marketed or developmental vaccines
- Table 10: Cephalosporins' spectrum of activity by generation
- Table 11: Antibiotic class sales by volume and value, 7MM, 2006
- Table 12: Late-stage pipeline antibiotic products by trial phase,
indication and grouping, 2007
- Table 13: Top five Antibacterial companies by 2006 revenues versus
rest of market
- Table 14: Top five antibacterial companies by 2006 revenues versus
rest of market
- Table 15: Pfizer SWOT analysis for the antibacterials market
- Table 16: Pfizer antibiotics portfolio overview, 2002-06
- Table 17: Johnson & Johnson SWOT analysis for the antibacterials
market
- Table 18: Johnson & Johnson antibiotics portfolio overview, 2002-06
- Table 19: Abbott SWOT analysis for the antibacterials market
- Table 20: Abbott antibiotics portfolio overview, 2002-06
- Table 21: Novartis SWOT analysis for the antibacterials market
- Table 22: Novartis antibiotics portfolio overview, 2002-06
- Table 23: Sanofi-Aventis SWOT analysis for the antibacterials market
- Table 24: Sanofi-Aventis antibiotics portfolio overview, 2002-06
- Table 25: Systemic antifungals versus other antifungal sales, 2006
- Table 26: Mortality due to invasive mycoses
- Table 27: Nosocomial bloodstream infection organism distribution in
the US, 2004
- Table 28: Predominant and emerging opportunistic fungal pathogens of
clinical significance, 2007
- Table 29: Types of immunocompromise, causes and associated fungal
pathogens
- Table 30: Indexed 7MM antifungal sales by ATC - indexed volume and
value sales, 2002-06, actual sales (SUm and $m) 2006, and CAGR (%) 2002-06
- Table 31: Indexed 7MM J2A0 ATC antifungal sales by class - Indexed
volume and value sales, 2002-06, actual sales (SUm and $m) 2006, and CAGR
2002-06%
- Table 32: 7MM antifungal market key volume and value sales dynamics by
region - US, M5EU, Japan, 2002-06
- Table 33: Top five Antifungal companies by 2006 revenues versus rest
of market
- Table 34: Top five antifungal companies by 2006 revenues versus rest
of market
- Table 35: Novartis SWOT analysis for the antifungals market
- Table 36: Novartis antifungals portfolio overview, 2002-06
- Table 37: Pfizer SWOT analysis for the antifungals market
- Table 38: Pfizer antifungals portfolio overview , 2002-06
- Table 39: Merck & Co SWOT analysis for the antifungals market
- Table 40: Merck & Co antifungals portfolio overview, 2002-06
- Table 41: Johnson & Johnson SWOT analysis for the antifungals
market
- Table 42: Johnson & Johnson antifungals portfolio overview, 2002-06
- Table 43: Astellas SWOT analysis for the antifungals market
- Table 44: Astellas Pharma antifungals portfolio overview, 2002-06
- Table 45: HCV - treatment options, 2007
- Table 46: HBV - treatment options, 2007
- Table 47: Populations targeted for influenza vaccination, US, 2003
- Table 48: Marketed influenza antivirals, 7MM, 2007
- Table 49: Marketed RSV antiviral
- Table 50: The human herpesviruses (HHV) fall into three sub-families
- Table 51: Marketed HSV antivirals, 7MM, 2007
- Table 52: Marketed VZV antivirals, 7MM, 2007
- Table 53: Marketed CMV antivirals, 7MM, 2007
- Table 54: 7MM antiviral sales by subsector - HSV, CMV and similar,
hepatitis, respiratory and other molecule sales dynamics by volume and
value (%), 2002-06
- Table 55: Indexed 7MM antivirals market by sector - hepatitis, HSV CMV
and similar, respiratory and other antivirals, 2002-06 and CAGR
- Table 56: 7MM indexed respiratory virus drug sales 2002-06
- Table 57: 7MM antiviral sales by geographic region, 2002-06
- Table 58: Top five antiviral companies by 2006 revenues versus rest of
market, 2002-06
- Table 59: Top five antifungal companies by 2006 revenues versus rest
of market
- Table 60: GSK SWOT analysis for the antivirals sector
- Table 61: GSK antivirals portfolio overview
- Table 62: Roche SWOT analysis for the antivirals sector
- Table 63: Roche antivirals portfolio overview, 2002-06
- Table 64: Ribavirin, interferons and pegylated interferons -
milestones in the Schering Plough/Roche HCV battle
- Table 65: Schering-Plough SWOT analysis for the antivirals sector
- Table 66: Schering Plough antivirals portfolio overview, 2002-06
- Table 67: Novartis SWOT analysis for the antivirals sector
- Table 68: Novartis antivirals portfolio overview, 2002-06
- Table 69: Gilead SWOT analysis for the antivirals sector
- Table 70: Gilead antivirals portfolio overview, 2002-06
- Table 71: Changing drivers of demand in HIV, 2007
- Table 72: 7MM HIV sales by class and product line composition, 2006
- Table 73: Regional HIV sales dynamics, 7MM, 2006
- Table 74: Top five HIV companies by combined revenues versus rest of
market, 7MM, 2006
- Table 75: Top five HIV companies by company revenues versus rest of
market, 7MM, 2006
- Table 76: GSK SWOT analysis for the HIV market
- Table 77: GSK - HIV portfolio overview, 2007
- Table 78: Agenerase and Lexiva background
- Table 79: Gilead SWOT analysis for the HIV market
- Table 80: Gilead - HIV portfolio overview, 2007
- Table 81: BMS SWOT analysis for the HIV market
- Table 82: BMS - HIV portfolio overview, 2007
- Table 83: Abbott SWOT analysis for the HIV market
- Table 84: Abbott -HIV portfolio overview, 2007
- Table 85: Roche SWOT analysis for the HIV market
- Table 86: Roche - HIV portfolio overview, 2007
- Table 87: FDCs and original brands - overlaps in market exclusivity
and potential revenue extension periods, 2007
- Table 88: HIV FDCs currently available in India
- Table 89: Antiviral market subdivisions by molecule
- Table 90: US antiviral volume and value sales dynamics by therapeutic
area
- Table 91: M5EU antiviral volume and value sales dynamics by
therapeutic area
- Table 92: Japan antiviral volume and value sales dynamics by
therapeutic area
- Table 93: Hepatitis antiviral volume and value sales dynamics by
geographic area
- Table 94: HSV, CMV and similar antivirals volume and value sales
dynamics by geographic area
- Table 95: Respiratory antivirals volume and value sales dynamics by
geographic area
- List of Figures
- Figure 1: Key dynamics - Infectious disease versus other key
therapeutic sectors, 7MM, 2002-06
- Figure 2: Infectious disease overview - key volume and value sales
dynamics by sector, 7MM, 2002-06
- Figure 3: Infectious disease overview - market attractiveness by
sector, 7MM, 2006
- Figure 4: Leading original and branded molecule sales versus rest of
market, 7MM, 2006
- Figure 5: Top 10 companies by revenue across the antibiotic,
antifungal, antiviral and HIV sectors, 7MM, 2006
- Figure 6: Top 10 players' infectious disease portfolio
characteristics, 7MM, 2006
- Figure 7: Top 10 company portfolio sector bias across the antibiotic,
antifungal, antiviral and HIV sectors, 7MM, 2006
- Figure 8: Top 10 players - Portfolio bias, performance and market
attractiveness, 7MM, 2006
- Figure 9: Regional revenues - top 10 companies, rest of market and
total market sales across the antibiotic, antifungal, antiviral and HIV
sectors, 7MM, 2006
- Figure 10: Antibiotic class sales by volume and value, 7MM, 2006
- Figure 11: Defining the market - acquisition, onset and treatment
settings for severe bacterial infections
- Figure 12: Antibiotic indexed volume and value sales, 6MM, 2002-06 -
branded versus non-branded sales, hospital and retail sectors
- Figure 13: 6MM Antibiotic sales - branded versus non-branded sales,
hospital and retail sectors
- Figure 14: Regional variations in class volume and value antibiotic
sales, 2006
- Figure 15: Comparative concentration of players in the antibiotic,
antifungal, antiviral and HIV markets - cumulative number of companies per
decile of sector market share, 2006
- Figure 16: Comparative concentration of product sales in the
antibiotic, antifungal, antiviral and HIV markets - cumulative market
share of top selling molecules, 2006
- Figure 17: Leading molecules by original and license brand sales, and
hospital/retail bias, 2006
- Figure 18: Top five antibacterial companies by 2006 revenues versus
rest of market
- Figure 19: Pfizer key antibiotics brand summary, 2007
- Figure 20: The antifungal drug explosion - drug development since the
1950s
- Figure 21: Cellular targets of antifungal classes
- Figure 22: Changing spectrum of invasive candidiasis species: episodes
per 1,000 admissions, 1988-1992
- Figure 23: Changing spectrum of invasive moulds: incidence per 1,000
patient days, 2000-03
- Figure 24: Indexed 7MM antifungal volume and value sales by ATC4,
2002-06
- Figure 25: 7MM J2A0 ATC antifungal volume and value sales by class,
2002-06
- Figure 26: Indexed US echinocandin wholesale pricing tactics by
quarter, Q2 2005-Q2 2007
- Figure 27: 7MM regional sales trends - US, M5EU and Japan volume and
value sales and growth rates, 2002-06
- Figure 28: Distribution of 7MM antifungal companies by volume and
value sales, 2002 and 2006
- Figure 29: Top five antifungal companies by 2006 revenues versus rest
of market
- Figure 30: Market focus of top five antifungal companies, 2007
- Figure 31: HBV - impact of vaccination on case numbers, US, 1978-2006
- Figure 32: 7MM antiviral volume and value sales by subsector, 2002-06
- Figure 33: 7MM hepatitis molecule sales by type - interferons,
pegylated interferons and other antivirals, 2002-06
- Figure 34: 7MM indexed volume sales - pegylated versus standard
interferons, 2002-06
- Figure 35: 7MM indexed respiratory virus drug sales, 2002-06
- Figure 36: HSV, CMV and similar - molecule sales dynamics by main
indication, 7MM, 2005-06
- Figure 37: 7MM antiviral sales by geographic region, 2002-06
- Figure 38: Top five antiviral companies by 2006 revenues versus rest
of market
- Figure 39: HIV timelines - key events, 1981-2007
- Figure 40: HIV market firsts - drug development since1986
- Figure 41: 7MM HIV sales by class, 2003-06
- Figure 42: 7MM HIV sales by class and product line composition, 2006
- Figure 43: Major patent expiries of HIV agents and barriers to generic
appeal, 2004-2016
- Figure 44: Top five HIV companies by company revenues versus rest of
market, 7MM, 2006
- Figure 45: Single products and FDCs - portfolio rejuvenation strategies
|
Related Report
|
View Cart
